Advertisement


Roland Seiler, MD, on Bladder Cancer: Subtypes and Treatment Response (German Language Version)

2017 Genitourinary Cancers Symposium

Advertisement

Roland Seiler, MD, of the University of British Columbia, discusses in German a way to identify molecular subtypes of muscle-invasive bladder cancer, the varying responses to cisplatin-based neoadjuvant chemotherapy, and which patients show the most benefit. (Abstract 281)



Related Videos

Bladder Cancer

Emma Hall, PhD, on Bladder Cancer: Results From the BC2001 Trial

Emma Hall, PhD, of the Institute of Cancer Research, London, discusses long-term outcomes with chemoradiotherapy vs radiotherapy alone, and standard vs reduced high-dose volume radiotherapy in muscle-invasive bladder cancer. (Abstract 280)

Solid Tumors

Lawrence H. Einhorn, MD, on Testicular Cancer: The Keynote Lecture

Lawrence H. Einhorn, MD, of the Indiana University Simon Cancer Center, summarizes his keynote lecture on the controversies in management of clinical stage I testicular cancer and the long-term consequences of platinum combination chemotherapy.

Solid Tumors

George J. Bosl, MD, and Karim Fizazi, MD, PhD, on Germ Cell Tumors and Treatment Intensification: Pros and Cons

George J. Bosl, MD, of Memorial Sloan Kettering Cancer Center, and Karim Fizazi, MD, PhD, of Gustave Roussy and the University of Paris Sud, offer the “pro” and “con” viewpoints for treatment intensification in patients with poor-prognosis germ cell tumors with unfavorable marker decline.

Kidney Cancer

Rana R. McKay, MD, on RCC: Continuing Benefit After Halting Treatment

Rana R. McKay, MD, of the University of California, San Diego, discusses study findings on PD-1/PD-L1 responders with metastatic renal cell carcinoma who discontinue therapy for immune-related adverse events. (Abstract 467)

Kidney Cancer

Sumanta K. Pal, MD, on RCC and Tumor Profiling

Sumanta K. Pal, MD, of the City of Hope, discusses the evolution of circulating tumor DNA profile from first-line to second-line therapy in metastatic renal cell carcinoma. (Abstract 434)

Advertisement

Advertisement




Advertisement